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Abstract
Consensus guidelines exist for genotype-guided fluoropyrimidine dosing based on variation in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines
have not been widely implemented in North America and most studies of pretreatment
DPYD screening have been conducted in Europe. Given regional differences in treatment practices and rates of adverse events (AEs), we investigated the impact of pretreatment DPYD genotyping on AEs in a Canadian context. Patients referred for DPYD
genotyping prior to fluoropyrimidine treatment were enrolled from December 2013
through November 2019 and followed until completion of fluoropyrimidine treatment.
Patients were genotyped for DPYD c.1905+1G>A, c.2846A>T, c.1679T>G, and
c.1236G>A. Genotype-guided dosing recommendations were informed by Clinical
Pharmacogenetics Implementation Consortium guidelines. The primary outcome
was the proportion of patients who experienced a severe fluoropyrimidine-related AE
(grade ≥3, Common Terminology Criteria for Adverse Events version 5.0). Secondary
outcomes included early severe AEs, severe AEs by toxicity category, discontinuation of fluoropyrimidine treatment due to AEs, and fluoropyrimidine-related death.
Among 1394 patients, mean (SD) age was 64 (12) years, 764 (54.8%) were men, and
47 (3.4%) were DPYD variant carriers treated with dose reduction. Eleven variant carriers (23%) and 418 (31.0%) noncarriers experienced a severe fluoropyrimidine-related
AE (p = 0.265). Six carriers (15%) and 284 noncarriers (21.1%) experienced early
severe fluoropyrimidine-related AEs (p = 0.167). DPYD variant carriers treated with
genotype-guided dosing did not experience an increased risk for severe AEs. Our data
support a role for DPYD genotyping in the use of fluoropyrimidines in North America.
Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Dihydropyrimidine dehydrogenase (DPD) deficiency is associated with
fluoropyrimidine-related adverse events (AEs), and screening for DPD deficiency can
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.
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be carried out using DPYD genotype testing of clinically relevant variants, as noted in
the Clinical Pharmacogenetics Implementation Consortium guidelines.
WHAT QUESTION DID THIS STUDY ADDRESS?
Given the paucity of data relating to pretreatment use of DPYD genotyping in North
America, this Canadian study adds new insights to the clinical impact of DPYD
testing.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
DPYD genotype-
guided dosing can ameliorate fluoropyrimidine-
related AE risk
for patients treated with fluoropyrimidine dose and regimens prescribed in North
America.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Although the European Medicines Agency supports DPD deficiency screening, this
study suggests that similar efforts should be undertaken in North America.

I N T RO D U C T ION
Five-fluorouracil (5-FU) and capecitabine are fluoropyrimidines used in the treatment of solid tumours.1-4 Unfortunately,
~30% of patients experience severe fluoropyrimidine-related
toxicity.5,6 Dihydropyrimidine dehydrogenase (DPD, gene
name DPYD) is the rate-limiting enzyme in fluoropyrimidine catabolism.7 DPD deficiency increases the risk of
fluoropyrimidine-related toxicity,8 and there are heritable
DPYD variants associated with decreased enzyme function
and thereby DPD deficiency.9 Meta-analyses have narrowed
the list of clinically relevant genetic variants allowing the implementation of genotype-guided dosing.10-12
In 2013, the Clinical Pharmacogenetics Implementation
Consortium (CPIC) published a consensus guideline detailing fluoropyrimidine dosing recommendations for 3
DPYD variants associated with reduced enzymatic activity: DPYD c.1905+1G>A (*2A, rs39818290), c.2846A>T
(rs67376798), and c.1679T>G (*13, rs55886062).13 For
heterozygous carriers of an individual variant, a 50% dose
reduction was recommended, whereas avoidance of fluoropyrimidines was recommended for homozygous or compound
heterozygous variant carriers. A fourth intronic variant,
DPYD c.1129-5923C>G (rs75017182, in linkage disequilibriumwith DPYD c.1236G>A [rs56038477]) was added to the
guideline in 2017.9 These recommendations were also refined
based on enzymatic activity scores (AS).14 The AS of each
patient is the sum of the individual alleles where each allele
is assigned a score of 0 to 1 based on functional characterization. The AS of clinically relevant alleles are 0 for DPYD
c.1905+1G>A or c.1679T>G and 0.5 for DPYD c.2846A>T
or c.1129-5923C>G. A 25% to 50% dose reduction was recommended for intermediate metabolizers with an AS of 1.5
and a 50% dose reduction was recommended for an AS of 1
and avoidance for an AS of 0 to 0.5. In 2018, results from
Henricks et al.15 led to further updates of the CPIC guidelines

to recommend a 50% dose reduction for AS of either 1 or
1.5.16 In addition, following a well-tolerated initial dose reduction, the CPIC encourages cautious dose escalation and
with concurrent therapeutic drug monitoring if available. Of
note, the CPIC guidelines provide reference for patients with
available genotype data and do not comment on the necessity
of preemptively determining the DPYD genotype.
In addition to the CPIC guidelines for response to known
DPYD variants, Dutch and French initiatives have published
guidelines that explicitly recommend DPD deficiency screening prior to fluoropyrimidine therapy.17,18 Despite this, adoption of pretreatment DPYD genotyping in Canada has been
limited and currently is widely accessible only in Quebec.
Given the abundance of data linking complete DPD deficiency
to severe toxicity, a randomized controlled trial of pretreatment
DPD deficiency screening was considered to be inappropriate
for our center. The only two-arm comparative study of DPD
deficiency screening was terminated prematurely due to the
fluoropyrimidine-related death of a DPD-deficient patient in
the control arm.19 However, two prospective DPYD single arm
genotype-guided studies were completed in the Netherlands,
the first examined the impact of one variant (c.1905+1G>A),20
and the second assessed four variants (c.1905+1G>A,
c.2846A>T, c.1679T>G, and c.1236G>A).15 These studies
demonstrated that genotype-guided dosing reduces the risk of
adverse events (AEs) for DPYD variant carriers in a European
population compared to the historical rate in DPYD variant
carriers receiving the standard of care.
In contrast, the impact of pretreatment DPYD genotype-
guided fluoropyrimidine dosing in North America is unpublished. There is an important distinction between results from
a European population and the potential results in a North
American population. Work by Haller et al. has identified
regional variation in fluoropyrimidine-related AEs between
the United States and Europe.21 Therefore, there is a need for
regional data to support regional implementation. Here, we
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conducted a study to determine the impact of pretreatment
DPYD genotype-guided dosing on patient safety at a tertiary
care center in London, Ontario, Canada. We hypothesized
that DPYD variant carriers who received a genotype-guided
dosing would have no greater risk of fluoropyrimidine-
related AEs as compared with noncarriers.

PAT IE N TS A N D ME T H O D S
Study Sample
We conducted a single-
center retrospective study of patients referred to the Personalized Medicine clinic at London
Health Sciences Centre (LHSC), London, Ontario, Canada,
for DPYD genotype testing between December 1, 2013,

and November 30, 2019. The study was approved by the
Institutional Review Board at Western University and all patients provided written informed consent. Of 1945 patients
referred for testing, 1845 were tested prior to fluoropyrimidine treatment. At initiation, the study was based on the 2013
CPIC guidelines13; however, in response to the 2017 update,9
the DPYD c.1236G>A variant was added to the testing panel
in May 2018. Consequently, 41 c.1236G>A carriers identified retrospectively were removed from the study as they
did not receive appropriate genotype-guided dosing. Two
compound heterozygous carriers were identified among the
genotype-guided patients and the treating oncologists were
advised to select an alternative therapy. There were 1394
patients who initiated treatment through LHSC prior to
December 1, 2019, that were included in the genotype-guided
study (Figure 1, baseline characteristics are summarized in

Paents genotyped for DPYD
(N = 1,945)

Paents tested pre-treatment
(N = 1,845)

Excluded (N = 100)
• Referred following a suspected
fluoropyrimidine-related toxicity
(post-AE)
Excluded (N = 203)
• Seen on external referral (N = 199)
• No cancer diagnosis (N = 4)

Paents planned to start a
fluoropyrimidine
(N = 1,642)

Paents who received a fluoropyrimidine
during study period
(N = 1,462)

Excluded (N = 180)
• Physician deemed paent not
clinically suitable for
fluoropyrimidines aer referral
(N = 121)
• Paent chose to decline
fluoropyrimidine therapy (N = 56)
• due to genotype (N = 5)
• other reasons (N = 51)
• Compound heterozygous variant
carriers (N = 2)
• Paent started chemotherapy aer
study period (N = 1)

Lost to Follow-up (N = 26)

Paents followed (N = 1,436)

Paents treated as
DPYD variant carriers
using genotype-guided
dosing
(N = 47)

Paents treated as
DPYD variant noncarriers using standard
dosing
(N = 1,389)

DPYD variant carriers
treated with genotypeguided dosing
(N = 47)

DPYD variant noncarriers treated with
standard dosing
(N = 1,347)

Genotype-guided cohort

Excluded (N = 1)
• Undetermined DPYD
c.1236G>A carrier status
Retrospecvely
idenfied DPYD
c.1236G>A carriers
treated with standard
dosing
(N = 41)

Retrospecve sample

F I G U R E 1 Flow diagram illustrating
the study cohort. AE, adverse event; DPYD,
dihydropyrimidine dehydrogenase
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Table 1). Prior chemotherapy, radiation therapy, concurrent
antineoplastic therapies, and other concomitant medications
were allowed. Baseline characteristics for patients lost to
follow-up are shown in Table S1.

DPYD genotype testing and dosing
recommendations
Whole blood samples were collected from each patient
and DNA was extracted using the MagNA Pure Compact
Instrument (Roche). DNA was assessed on a ViiA 7 real-time
polymerase chain reaction system (ThermoFisher Scientific)
using TaqMan allelic discrimination assays (ThermoFisher
Scientific) for DPYD c.1905+1G>A (assay ID:
C__30633851_20), c.2846A>T (assay ID: C__27530948_10),
c.1679T>G (assay ID: C__11985548_10), and c.1236G>A
(assay ID: C__25596099_30). Variant c.1236G>A is known
to be in strong linkage disequilibrium with c.1129-5923C>G
and was used as a proxy for genotyping, which is in alignment with the CPIC guidelines.
Results and dosing recommendations were provided to
the referring physicians within the patients’ electronic health
records (EHRs). Recommendations were as follows: for noncarriers, dose as per standard of care; for simple heterozygous
carriers, apply a 50% initial dose reduction, and consider
attempting dose escalation in subsequent cycles pending
patient tolerance. A 25% to 50% initial dose reduction was
recommended for heterozygous carriers of c.1236G>A upon
its addition to the testing panel, with the same additional recommendation to attempt dose escalation based on patient tolerability. Avoidance of fluoropyrimidines in homozygous or
compound heterozygous variant carriers was recommended
throughout the study, recommendations are summarized in
Table 2. Final treatment decisions were at the discretion of
the treating oncologist.

Data collection
Treatment data, including regimen, dose, and radiation use,
were collected from LHSC pharmacy records. Clinical variables and toxicity data were obtained by standardized review
of the patients’ EHRs by trained study personnel, each record
was reviewed independently by two study members. Toxicity
data were recorded from clinic notes, admission records,
discharge summaries, and emergency department reports.
Severe AEs included grade greater than or equal to 3 toxicities according to the National Cancer Institutes’ Common
Terminology Criteria for Adverse Events (CTCAE) version
5.0.22 Only those AEs determined to be possibly, probably, or
definitely related to the fluoropyrimidine components were
included in the outcome, following the standard definitions
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proposed in the National Institutes of Health protocol template for phase II/III trials.23 Based on these principles, the
definitions require the AE to occur within 30 days of fluoropyrimidine administration, be pharmacologically plausible,
and not be attributable to another component of the regimen.
The effect of removing and reinstating the fluoropyrimidine
were also considered when these challenges occurred. Based
on the literature, the major toxicity categories considered
were gastrointestinal (including primarily: diarrhea, oral mucositis, and nausea/vomiting), myelosuppression (primarily
neutropenia/febrile neutropenia, as well as thrombocytopenia, and unexplained anemia), cardiac (sudden onset cardiac toxicity during fluoropyrimidine administration), and
Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome).
The remaining AEs, in which fluoropyrimidines were likely
contributors, were grouped under the other heading. The AEs
reported by the initial reviewers and attribution of causality
was reviewed by a medical oncology fellow under the supervision of a practicing medical oncologist. Conflicts in the
records were reviewed by the initial coders and the reviewing
medical oncologist. Patients were followed for their entire
treatment period and until toxicity resolved.

Outcomes
The primary outcome was severe (grade ≥3, CTCAE version
5.0) fluoropyrimidine-related AEs. We included a secondary
outcome of early fluoropyrimidine-related AEs during the
first two cycles of treatment. Secondary outcomes further
included fluoropyrimidine-related AEs by toxicity category,
proportion of patients discontinuing fluoropyrimidines due to
fluoropyrimidine-related AEs, and fluoropyrimidine-related
deaths.

Statistical methods
The primary outcome was compared between DPYD variant carriers and noncarriers using a χ2 test. Other dichotomous outcomes were compared using χ2 or Fisher’s Exact
test as appropriate. Fisher’s Exact tests were used when cell
values in contingency tables were less than or equal to 5. A
test for noninferiority between AEs in the variant carriers
and noncarriers was performed using a two-one sided test
of equivalence. The smallest effect size of interest (SESOI)
was determined using the lower bound for the 95% confidence interval (CI) of the risk for the c.1236G>A variant
carriers in the literature multiplied by the event rate in noncarriers in this study. The c.1236G>A demonstrated the
lowest increased risk and using this value to set the SESOI
was considered a conservative approach. Unadjusted relative risk was used to show the risk of grade greater than
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Genotype-guided cohort

Retrospective
sample

Noncarrier
(N = 1347)

Carrier
(N = 47)

c.1236G>A
carrier (N = 41)

Female

605 (44.9)

25 (53)

13 (31)

Male

742 (55.1)

22 (47)

28 (68)

45 (96)

40 (98)

Characteristic

T A B L E 1 Baseline patient
characteristics

Sex, N (%)

Race, N (%)
White

1267 (94)

a

Other

32 (2.4)

1 (2)

1 (2)

Unknownb

48 (3.6)

1 (2)

0 (0)

64 (12)

62 (13)

66 (10.4)

1.9 (0.3)

1.9 (0.2)

1.94 (0.27)

Colorectal

779 (57.8)

25 (53)

21 (51)

Gastric and esophagus

189 (14.0)

7 (15)

5 (12)

Pancreas

106 (7.9)

6 (13)

2 (5)

Breast

89 (6.6)

3 (6)

1 (2)

Anus

48 (3.6)

1 (2)

3 (7)

Age, mean (SD), years
2

Body surface area, mean (SD), m
Tumor site, N (%)

Head and neck

27 (2.0)

2 (4)

3 (7)

109 (8.1)

3 (6)

6 (15)

Capecitabine with radiation

277 (20.6)

11 (23)

11 (27)

Capecitabine monotherapyd

229 (17.0)

7 (15)

8 (20)

Capecitabine with oxaliplatin

130 (9.7)

2 (4)

2 (5)

68 (5.0)

3 (6)

1 (2)

FOLFOXd

228 (16.9)

8 (17)

9 (22)

FOLFIRI/FOLFIRINOX

135 (10.0)

8 (17)

0 (0)

5-FU with cisplatin/carboplatin

128 (9.5)

4 (9)

3 (7)

152 (11.3)

4 (9)

7 (17)

Otherc
Regimen, N (%)

Capecitabine with other agentse

f

5-FU with other agents
DPYD genotype, N (%)

1347 (100)

0 (0)

0 (0)

c.2846A>T heterozygous

Wild-type

0 (0)

19 (40)

0 (0)

c.1905+1G>A heterozygous

0 (0)

9 (19)

0 (0)

c.1679T>G heterozygous

0 (0)

1 (2)

0 (0)

c.1236G>A heterozygous

0 (0)

18 (38)

41 (100)

Abbreviation: 5-FU, 5-fluorouracil.
a

Other includes Black, Asian, and Indigenous.

b
c

Due to self-declaration of race not all patients opted to provide this information and it remains unknown.

Other included appendix and small bowel, genitourinary, hepatobiliary, and primary site unknown.

d
e
f

Including with and without biologic agents.

Including gemcitabine, lapatinib, temozolomide, docetaxel, epirubicin, and mitomycin + radiation.

Including Degramount, FEC-D, and FLOT regimens, in addition to mitomycin + radiation.

or equal to 3 AE in our genotype-guided study and within
the literature. Unadjusted relative risks are reported due
to the low number of events among variant carriers, and
for consistency with previous genotype-guided studies. A
multivariable logistic regression determined the adjusted

odds ratios and is available within the supplementary data.
A Wilcoxon Mann-Whitney U test was used to compare
the number of cycles administered between variant carriers and noncarriers. Descriptive statistics are shown using
number (percentage), mean (SD), and median (interquartile

IMPACT OF PRETREATMENT DIHYDROPYRIMIDINE DEHYDROGENASE GENOTYPE-GUIDED
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TABLE 2
in the study

Dose Recommendations used

2

Standard dosing

-/c.1236G>A

1.5

25%–50% Dose reduction

-/c.2846G>A

1.5

50% Dose reduction

-/c.1905+1G>A

1

-/c.1679T>G

1

c.1236G>A/c.2846A>Tc

1

c.1236G>A/c.1905+1G>A

0.5

c.1236G>A/c.1679T>G

0.5

c.2846A>T/c.1905+1G>A

0.5

c.2846A>T/c.1679T>G

0.5

Noncarrier

-/-
b

c.1905+1G>A/c.1679T>G
Homozygous
carriers

1343
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Compound
heterozygous
carriers
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ASa

Variant Status
Simple heterozygous
carriers

  

d

Avoid fluoropyrimidines

0

c.1236G>A/c.1236G>A

1

c.2846A>T/c.2846A>Td

1

c.1905+1G>A/c.1905+1G>A

0

c.1679T>G/c.1679T>G

0

Abbreviations and Symbols: AS, activity score; -, negative for tested variants.
a

The predicted AS, assuming nontested variants are functional with an AS of 1 per allele.

b

The c.1236G>A was added to the testing panel in 2018 as a proxy for haplotype-B3 and the causative variant
DPYD c.1129-5923C>G.

c
Despite an AS of 1, we recommend avoiding fluoropyrimidines in c.1236G>A/c.2846A>T patients, however,
no patients with this genotype were detected.
d

Despite an AS of 1, we recommend avoiding fluoropyrimidines in c.1236G>A/c.1236G>A or c.2846A>T/
c.2846A>T patients, however, no patients with this genotype were detected.

range [IQR]) as applicable. Reported p values are for two-
sided tests, with p < 0.05 considered significant. All analyses were performed using R (version 4.0.2; R Foundation
Inc.; http://cran.r-project.org/). In addition, the package
“tidyverse” was used for data processing and both “epiR”
and “TOSTER” were used for analysis, the script used for
analysis is available in the supplementary materials.

RE S U LTS
Study population
Among the 1394 patients provided genotype-guided dosing,
the mean (SD) age was 64 (12) years and 764 (54.8%) were
men. The most common primary tumor site was colorectal
(804, 57.7%). Overall fluoropyrimidine use was distributed
between capecitabine (727, 52.2%) and 5-FU (667, 47.8%).
Forty-
seven patients (3.4%) were heterozygous carriers
for one of DPYD c.2846A>T (19, 1.4%), c.1236G>A (18,
1.3%), c.1905+1G>A (9, 0.6%), or c.1679T>G (1, <0.1%).
The retrospectively identified c.1236G>A carriers did not
appear to differ from the primary study, with the most common primary tumor site being colorectal (21, 51%), and an
approximately equal use of capecitabine (23, 56%), and 5-FU
(18, 44%). However, the retrospective sample contained

more men (28/41, 68%) than women. The baseline characteristics are summarized in Table 1.

Physician compliance with dose
recommendations
We confirmed that variant carriers were treated according to
the dose recommendations provided to the treating oncologist. The mean initial dose intensity was 52% (18) of ideal for
variant carriers and 87.4% (15.2) for noncarriers (Table 3).
Variant carriers received a median (IQR) of 6 (2–7) cycles
of fluoropyrimidine treatment, and noncarriers received a
median of 4 (2–6) cycles. We also assessed the mean dose intensity throughout the treatment period and found that variant
carriers received a mean dose intensity over the total treatment period of 55% (15), whereas mean intensity for noncarriers was 84.2% (14.7).

Toxicity outcomes
There were no significant differences in the primary or secondary toxicity outcomes between genotype-
guided variant carriers and noncarriers. We observed that 23% (11/47)
of variant carriers, and 31.0% (418/1347) of noncarriers
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Severe fluoropyrimidine-related adverse events during total treatment period
Retrospective
sample

Genotype-guided cohort
Noncarrier
(N = 1347)

Carrier
(N = 47)

P
valuea

c.1905+1G>A
(N = 9)

c.2846A>T
(N = 19)

c.1679T>G
(N = 1)

c.1236G>A
(N = 18)

c.1236 G>A
(N = 41)

Initial dose intensity,
mean (SD)

87.4 (15.2)

52 (18)

NA

47 (16)

47 (21)

43 (NA)

59 (13)

85 (17)

Dose intensity, mean
(SD)

84.2 (14.7)

55 (13)

NA

46 (8)

55 (15)

50 (NA)

59 (12)

85 (17)

Treatment cycles,
median (IQR)

4 (2–6)

6 (2–7)

0.201

6 (2–8)

6 (4–8)

6 (NA)

4 (2–6)

2 (2–4)

Total severe AEsb (all
cycles), N (%)

N (%)

Globalc

418 (31.0)

11 (23)

0.265

3 (33)

5 (26)

0 (0)

3 (17)

14 (34)

Gastrointestinal

167 (12.4)

6 (12)

0.940

2 (22)

2 (11)

0 (0)

2 (11)

7 (17)

Myelosuppression

157 (11.7)

6 (12)

0.816

2 (22)

2 (11)

0 (0)

2 (11)

2 (5)

Cardiac

33 (2.4)

0 (0)

0.625

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

HFS

35 (2.6)

1 (2)

>0.99

0 (0)

1 (5)

0 (0)

0 (0)

2 (5)

113 (8.4)

2 (4)

0.425

1 (11)

1 (5)

0 (0)

0 (0)

5 (12)

AE-related death

10 (0.7)

0 (0)

>0.99

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Discontinued
treatmentf

232 (17.2)

10 (21)

0.437

2 (22)

3 (16)

0 (0)

5 (28)

7 (17)

d

Other

e

N (%)

N (%)

Abbreviations: AEs, adverse events; HFS, hand-foot syndrome; IQR, interquartile range; NA, not applicable.
a

P value for treatment cycles was calculated based on Wilcoxon-Mann-Whitney test. P values for fluoropyrimidine-related AEs calculated using the following tests:
Global, Gastrointestinal, Myelosuppression, and Discontinued Treatment utilized χ2 tests; Cardiac, HFS, Other, and AE-related Death utilized Fisher’s Exact Test.

b
c

Grade ≥3 by Common Terminology Criteria for Adverse Events version 5.0.

Global includes all fluoropyrimidine-related AEs grade ≥3 and fluoropyrimidine-related deaths. This does not include discontinuation.

d
e
f

Other grade ≥3 AEs included: fatigue, infections, neurotoxicities, and laboratory abnormalities.

At least one fluoropyrimidine-related AE contributed significantly to death.

Patients discontinuing treatment with fluoropyrimidines due to a fluoropyrimidine-related AE of any grade.

experienced severe fluoropyrimidine-
related AEs during
their total treatment periods (p = 0.265; Table 3). We next
examined severe fluoropyrimidine-related AEs that occurred
during the early cycles (1–2) of fluoropyrimidine treatment.
We found that 13% (6/47) of genotype-guided variant carriers compared to 21.4% (284/1347) of genotype-
guided
noncarriers experienced an early fluoropyrimidine-
related
AE (p = 0.167; Table 4). Secondary analyses of the major
AE categories, proportion discontinuing fluoropyrimidines
due to AEs and fluoropyrimidine-related deaths, during the
total treatment period or the first two cycles, did not show
any significant differences between genotype-guided variant carriers and noncarriers. Additionally, we performed
noninferiority testing comparing the risk for global severe
fluoropyrimidine-related AEs between carriers and noncarriers both during the total treatment and limited to the early
cycles (Figure 2). In both early and total treatment periods,
the CIs included no difference but did not cross the noninferiority margin. Therefore, we conclude that genotype-
guided variant carriers do not experience increased risk of
fluoropyrimidine-
related AEs compared with noncarriers

receiving the standard of care dosing practices. We determined the unadjusted relative risk (RR) of grade greater than
or equal to 3 fluoropyrimidine-related AEs in our genotype-
guided variant carriers to allow for comparison to literature
values (Table 5).11,15 We report unadjusted RR values due
to the small number of genotype-guided variant carriers in
our cohort and the literature. We obtained historical values
for RR of fluoropyrimidine-related AEs without genotype-
guidance from a meta-analysis by Meulendijks et al.11 In our
cohort, genotype-guided variant carriers were not at a significantly elevated risk for severe fluoropyrimidine-related AEs
compared with noncarriers. Indeed, with the recommended
50% dose reduction the RR was 1.08 (95% CI: 0.43–2.74)
for c.1905+1G>A carriers, and 0.85 (95% CI: 0.40–1.82)
for c.2846A>T carriers. With the recommended 25% to
50% dose reduction recommendations, the RR for genotype-
guided c.1236G>A carriers was 0.54 (95% CI: 0.19–1.52).
Finally, the single c.1679T>G carrier in our genotype-guided
cohort was treated with a 50% dose reduction and did not
suffer any fluoropyrimidine-related AEs during treatment.11
Additionally, we performed a secondary calculation of
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Early severe fluoropyrimidine-related AEs
Retrospective
sample

Genotype-guided cohort
Noncarrier
(N = 1347)
Early severe AEsb
(cycles 1–2), N (%)

N (%)

Globalc

Carrier
(N = 47)

P valuea

c.1905+1G>A
(N = 9)

c.2846A>T
(N = 19)

c.1679T>G
(N = 1)

c.1236G>A
(N = 18)

N (%)

c.1236 G>A
(N = 41)
N (%)

284 (21.1)

6 (13)

0.167

2 (22)

3 (16)

0 (0)

1 (5)

10 (24)

Gastrointestinal

131 (9.7)

3 (6)

0.616

1 (11)

1 (5)

0 (0)

1 (5)

5 (12)

Myelosuppression

0.401

102 (7.6)

5 (11)

2 (22)

2 (11)

0 (0)

1 (5)

1 (2)

Cardiac

26 (1.9)

0 (0)

>0.99

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

HFS

13 (1.0)

0 (0)

>0.99

0 (0)

0 (0)

0 (0)

0 (0)

2 (5)

68 (5.0)

2 (4)

>0.99

1 (11)

1 (5)

0 (0)

0 (0)

3 (7)

8 (0.6)

0 (0)

>0.99

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

137 (10.2)

5 (11)

2 (22)

1 (5)

0 (0)

2 (11)

4 (10)

d

Other

AE-related deathe
Discontinued
treatmentf

|

0.808

Abbreviations: AEs, adverse events; HFS, hand-foot syndrome.
a

P values for fluoropyrimidine-related AEs calculated using the following tests: Global utilized χ2 test; Gastrointestinal, Myelosuppression, Cardiac, HFS, Other, AE-
related death, and Discontinued Treatment utilized Fisher’s Exact Test.

b
c

Grade ≥3 by Common Terminology Criteria for Adverse Events version 5.0.

Global includes all fluoropyrimidine-related AEs grade ≥3 and fluoropyrimidine-related deaths. This does not include discontinuation.

d
e
f

Other AEs included: fatigue, infections, neurotoxicities, and laboratory abnormalities.

At least one fluoropyrimidine-related AE contributed significantly to death.

Patients discontinuing treatment with fluoropyrimidines due to a fluoropyrimidine-related AE of any grade.

multivariable logistic regression adjusting for age, sex, regimen, and initial intensity of therapy. We do not include this
in the primary report due to the small sample size of variants
and the potential for the introduction of bias during adjustment. However, we note that there were no significant differences from the unadjusted predictions and these results can
be found in Table S2.

Retrospectively identified DPYD
c.1236G>A carriers
DPYD c.1236G>A carriers identified retrospectively in May
2018 (N = 41) were removed from the genotype-guided cohort as they were treated as DPYD variant noncarriers. We
predicted that these c.1236G>A carriers would experience
an increased risk of fluoropyrimidine-related AEs given they
were treated with standard dosing. However, c.1236G>A
carriers treated with standard dosing did not experience an elevated toxicity profile (Table 3). In brief, 34% (14/41) of the
retrospectively identified c.1236G>A carriers experienced
a severe fluoropyrimidine-related AE during the total treatment period and 24% (10/41) experienced an early severe
fluoropyrimidine-related AE (Table 4). In summary, compared to the genotype-guided cohort, the unadjusted relative
risk of global severe fluoropyrimidine-related AEs was 1.09
(0.71–1.68).

DISCUSSION
We report the impact of pretreatment DPYD genotype-guided
fluoropyrimidine dosing on AEs in a Canadian hospital assessed through retrospective follow-up of the Personalized
Medicine Clinic. We show that when treated with genotype-
guided dosing for DPYD c.1905+1G>A, c.1679T>G,
c.2846A>T, or c.1236G>A, the proportion of variant carrying patients who experienced severe fluoropyrimidine-related
AEs was not statistically different from noncarriers. We found
that a 50% dose reduction for DPYD c.1905+1G>A and
c.2846A>T carriers ameliorated the severe fluoropyrimidine-
related AE risk compared to the historical RR for carriers treated with full dose (Table 5). Previously, Henricks
et al. reported that a 25% initial dose reduction in carriers
of DPYD c.2846A>T did not eliminate the elevated risk of
severe fluoropyrimidine-related AEs.15 Together these findings suggest that an initial 50% dose reduction is an appropriate dosing strategy for carriers of DPYD c.1905+1G>A and
c.2846A>T, consistent with the current CPIC guidelines.9
The Personalized Medicine Clinic attempted to provide DPYD genotype-guided dosing in alignment with the
best available evidence. Indeed, the genotyping for DPYD
c.1236G>A as a proxy for variant c.1129-5923C>G starting
in 2018 reflects the latest CPIC guideline recommendations
that note the association of c.1129-
5923C>G with severe
fluoropyrimidine-related AEs.11,24 In order to account for this
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(a)

Total Treatment Period

(b)

Proporon Difference

Early Treatment Period

Proporon Difference

F I G U R E 2 Plotting results of noninferiority comparison for global severe fluoropyrimidine-related AEs between genotype-guided variant
carriers and noncarriers. Difference is variant carriers minus noncarriers, less than zero genotype-guided variant carriers are at less risk than
standard of care noncarriers. The first panel compares proportion of severe AEs during total treatment period (a), the inferiority bound is 6.82%,
the genotype-guided variant carriers do not experience increased risk of severe AEs in the total treatment period. The second panel compares
proportion of severe AEs during early treatment period (b), the inferiority bound is 2.52%, the genotype-guided variant carriers do not experience
increased risk of severe AEs in the early treatment period. AE, adverse event; CI, confidence interval
TABLE 5

Unadjusted relative risk of severe fluoropyrimidine-related adverse events

DPYD variant

Genotype-guided dosing current
cohorta
RR (95% CI)d

Patients treated without genotype-guided
dosingb
RR (95% CI)d

Genotype-guided dosing
literature cohortc
RR (95% CI)d

c.1905+1G>A

1.08 (0.43–2.74)

2.87 (2.14–3.86)

1.31 (0.63–2.72)

c.2846A>T

0.85 (0.40–1.82)

3.11 (2.25–4.28)

2.00 (1.19–3.34)

4.30 (2.10–8.80)

NAe

1.72 (1.22–2.42)

1.69 (1.18–2.42)

e

c.1679T>G

NA

c.1236G>A

0.54 (0.19–1.52)

Abbreviations: CI, confidence interval; NA, not applicable; RR, relative risk.

a
Our genotype-guided cohort: 50% dose reduction recommended for carriers of c.1905+1G>A, c.2846A>T, and c.1679T>G; 25% −50% dose reduction for carriers of
c.1236G>A.
b

Meulendijks et al. historical cohort derived from a meta-analysis11: standard of care dosing with adjustment due to tolerability resulting in the assumption that given
no genotype was known the dose intensity was equivalent between DPYD variant carriers and noncarriers.

c
Henricks et al. genotype guided cohort16: 50% dose reduction recommended for carriers of c.1905+1G>A or c.1679T>G; 25% dose reduction for carriers of
c.2856A>T or c.1236G>A. Followed by dose escalation pending patient tolerance.
d

Unadjusted RRs with 95% CIs are discussed due to small sample size of variant carriers in genotype-guided cohorts. Risks are calculated compared with noncarriers
of the individual variant of interest.
e

Only one c.1679T>G carrier was detected in each genotype-guided cohort. In both cohorts, the carrier was treated with 50% dose reduction and did not suffer a
fluoropyrimidine-related adverse event.

in this analysis, we carried out retrospective genotyping for
DPYD c.1236G>A for patients who had been enrolled prior to
inclusion of this variant as part of the DPYD test panel. We hypothesized that our patients who were DPYD c.1236G>A carriers treated with standard dosing would exhibit an increased
risk of fluoropyrimidine-related AEs in alignment with previous meta-analysis data, as cited in the CPIC guidelines.11,14
However, the retrospectively identified DPYD c.1236G>A

carriers in our study did not demonstrate an increased risk. In
the meta-analysis by Meulendijks et al. that demonstrated an
increased risk associated with DPYD c.1236G>A, however,
the included studies consisted of only European populations
(N = 4261).11 Subsequently to the meta-analysis publication,
a large association study of American patients with colorectal
cancer (N = 1953) demonstrated no significant association between DPYD c.1129-5923C>G and fluoropyrimidine-related
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AEs (RR 1.27, 95% CI: 0.97–
1.67) in their population.25
However, in the American study, they also confirmed that the
proxy variant was in complete linkage disequilibrium with the
causal variant. Lee et al. did demonstrate a trend toward an
association and significance in a secondary outcome associating the c.1129-5923C>G variant with neutropenia.25 Given
the difference between these previous findings and the known
regional difference between the United States and European
populations, we suggest the lack of significant association in
our c.1236G>A carriers may reflect this difference. However,
this difference was not proven and may be due to the limited
sample size of retrospective c.1236G>A carriers in this study.
The CPIC currently supports a 50% dose reduction for DPYD
c.1236G>A carriers, followed by dose escalation if the patient
tolerates the reduced dose. More evidence is needed to elucidate the extent of the potential regional effect on carriers of
this variant. In the meantime, we continue to support the CPIC
recommendations for DPYD c.1236G>A carriers. Given the
uncertainty, therapeutic drug monitoring may be useful to
limit AEs during dose escalations.26

Limitations
The first major limitation of our study design is the experimental
design. A robust two-arm comparative study directly comparing genotype-guided dosing to standard of care therapy would
have provided stronger evidence to support these findings.
However, a two-arm comparative study was deemed inappropriate given the body of evidence associating DPYD variation
and fluoropyrimidine-related AEs prior to initiating the program at the Personalized Medicine Clinic. The retrospective
collection of AE outcomes also limits the design. However, as
listed in the Methods sections, systems were in place to limit
the bias of this data collection and the pragmatic nature was
necessary given limitations of the clinic at the time of study
initiation. As well, our study design lacks disease progression
or survival outcomes. However, it has previously been shown
that c.1905+1G>A carriers treated with a 50% starting dose reduction achieved the same fluoropyrimidine exposure as noncarriers with standard dosing.20 Additionally, a retrospective
survival analysis showed no difference in survival outcomes
between variant carriers receiving genotype-guided dosing and
noncarriers receiving standard dosing.27 These data suggest
that the DPYD variant carriers treated with a dose reduction
achieve the same systemic exposure and therapeutic outcomes.
The four variants tested in this study have been validated in
studies predominated by White people of European descent,
as was our study population. Additional DPYD variants may
play an important role in other patient populations (e.g., DPYD
c.557A>G in people of African descent).28 Further research
in other patient populations is needed to validate the utility of
DPYD genotype-guided dosing in more diverse populations.
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Finally, this study used DPYD genotype testing as a pretreatment screening method for DPD deficiency, however, we did
not assess other methods of detecting DPD deficiency in this
patient population.

CONCLUSION
Health Canada and the US Food and Drug Administration include warnings that DPD-deficient patients are at an increased
risk of severe AEs on fluoropyrimidine product labels.1-3
However, to date, neither agency has recommended any pretreatment screening methods despite consensus guidelines
from expert groups in Europe.17,18 In March of 2019, the French
Medicines Agency triggered a formal review of preemptive
DPD deficiency screening by the European Medicines Agency
(EMA), and, in April 2020, the EMA issued a recommendation for DPD deficiency testing prior to initiation of fluoropyrimidines. Our data support equivalent efforts to study and
implement DPD deficiency screening through DPYD genotype testing be undertaken within North America.
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